



(51) International Patent Classification:

C07K 7/02 (2006.01) *A61K 38/04* (2006.01)
C07K 5/02 (2006.01) *A61P 25/00* (2006.01)

(21) International Application Number:

PCT/IL2015/050488

(22) International Filing Date:

11 May 2015 (11.05.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/991,532 11 May 2014 (11.05.2014) US
62/137,846 25 March 2015 (25.03.2015) US

(71) Applicant: **TEL HASHOMER MEDICAL RESEARCH
INFRASTRUCTURE AND SERVICES LTD.** [IL/IL];
Tel Hashomer, The Chaim Sheba Medical Center, 52621
Ramat Gan (IL).

(72) Inventors: **CHAPMAN, Joab**; 24 Remez Street, 55212
Kiryat Ono (IL). **SHAVBIT-STEIN, Efrat**; 13 Tritch
Street, 69860 Tel Aviv (IL).

(74) Agents: **BOGIN, Liora** et al.; Webb & Co, P.O. Box
2189, 76121 Rehovot (IL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: PAR-1 BASED THERAPEUTIC CONJUGATES AND USES THEREOF

(57) Abstract: The present invention is directed to a peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C'-terminus of PAR-1, or an active variant thereof and a protease-disabling moiety. The present invention is further directed to pharmaceutical compositions comprising the peptide conjugate and use thereof for treating diseases and disorder associated with excessive PAR-1 activity.



PAR-1 BASED THERAPEUTIC CONJUGATES AND USES THEREOF

FIELD OF THE INVENTION

The present invention is directed to a peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C'-terminus of PAR-1, or an active variant thereof and a protease-disabling moiety. The present invention is further directed to pharmaceutical compositions comprising the peptide conjugate and use thereof for treating diseases and disorder associated with excessive PAR-1 activity.

BACKGROUND OF THE INVENTION

Protease activated receptors (PARs) are a family of four G protein coupled receptors numbered PAR-1 to PAR-4. Since its discovery in the early 90's, PAR-1 has been found in many tissues including the brain where it is found on several cell types including neurons, astrocytes and microglia. The first functions of PAR-1 described in neurons and glia involved cell survival and cell death. This dual effect is concentration dependent where at high levels of PAR-1 activation deleterious effects are seen and at lower levels protective effects are seen. PAR-1 carries all determinants required for thrombin recognition.

Many neurological diseases are known to be associated with increased inflammation and over activation of protease activated receptors (PARs) by protein factors of the coagulation cascade. This include, neuropathy which is commonly caused by diabetes mellitus, occurring in 60% of all diabetic patients.

Many studies have suggested that thrombin plays a role in angiogenesis and its inhibition reduces edema. Glioblastoma multiform, (GBM) is a rapidly growing brain tumor resulting in high mortality within month. Several processes characterize GBM including increased angiogenesis, edema formation and enhanced tumor cell proliferation.

US 2009/0281100 and US 2004/0092535 disclose a method of inhibiting a serine/threonine kinase using benzimidazole quinolinones, wherein the serine/threonine kinase is PAR-1, for treating diabetes, noninsulin dependent diabetes mellitus, Alzheimer's disease, bipolar disorder, cancer, autoimmune diseases and organ transplant rejection.

US 2012/0232097 and US 2009/0176803 disclose cinnamoyl-piperazine derivatives as PAR-1 antagonists and uses thereof for treating and/or preventive arterial/venous thrombosis,

acute coronary syndromes, restenosis, stable angina, heart rhythm disorders, myocardial infarction, hypertension, heart failure, stroke, inflammatory disorders, pulmonary diseases, gastrointestinal diseases, fibrosis development in chronic liver disease patients, cancer and skin diseases.

5 US 8,232,295 and 7,842,716 disclose methods for treating and/or preventing vascular events by inhibiting PAR-1 and/or PAR-4 using statins.

US 2007/0142272 discloses use of an activated protein C (APC), prodrug and/or a variant thereof as agonist of PAR-1 and/or PAR-3 and/or endothelial protein C receptor (EPCR) for providing neuroprotection, treating neurodegenerative disease and improving stress or
10 injury.

Despite efforts made in the field, there remains an unmet need in the art for potent inhibitors that inhibit or prevent over activation of PARs, especially, PAR-1.

SUMMARY OF THE INVENTION

15 The present invention provides novel peptide conjugates capable of targeting increased protease activity associated with diseases and disorders. The peptide conjugates of the invention are adapted to specifically protect PAR receptors from being over-activated. Surprisingly, the peptide conjugates of the invention were shown to inhibit thrombin activity, reduce thrombin-like activity generated by glioma-cells, inhibit proliferation of glioma cells, induce reduction in
20 glioblastoma multiform (GBM) tumors in vivo and reduced formation of edema associated with GBM. Advantageously, the peptide conjugates exert the aforementioned therapeutic activities at significantly low concentrations, within the range of nanomolars in vitro and micromolars in vivo, while known PAR1 inhibitors require much higher concentrations in order to exert an inhibitory activity. Moreover, the activity of the peptide conjugate is performed without
25 effecting coagulation. The remarkable efficacy at nanomolar concentrations suggests that the conjugates provide reduced toxicity and reduced occurrence of side effects, particularly, undesired internal bleeding.

There is provided a peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C'-
30 terminus of PAR-1 as set forth in SEQ ID NO: 17, or an active variant thereof and a protease-disabling moiety.

In some embodiments, the alpha-amino protecting moiety may be bound to the N'-terminus amino acid sequence of the peptide directly or via a linker.

In some embodiments, the protease-disabling moiety may be bound to the C'-terminus amino acid sequence of the peptide directly or via a linker.

5 In some embodiments, the alpha-amino protecting moiety may be selected from tosyl and tert-Butyloxycarbonyl.

In some embodiments, the alpha-amino protecting moiety may be tosyl or derivatives thereof.

In some embodiments, the peptide comprises the amino acid sequence Asp-Pro-Arg.

10 In some embodiments, the peptide comprises an amino acid sequence as set forth in any one of SEQ ID NO:1 to SEQ ID NO:17 and Asp-Pro-Arg, or an active variant thereof.

In some embodiments, the peptide comprises the amino acid set forth in SEQ ID NO:3, or an active variant thereof.

15 In some embodiments, the peptide comprises the amino acid set forth in SEQ ID NO:4, or an active variant thereof.

In some embodiments, the peptide moiety may consist of an amino acid sequence selected from the group consisting of Asp-Pro-Arg and SEQ ID NO: 1 to SEQ ID NO:17.

In some embodiments, the linker may be a peptide linker or an oligonucleotide linker.

In some embodiments, the protease-disabling moiety may be a substituted acetyl.

20 In some embodiments, the protease-disabling moiety may be selected from the group consisting of sulfonylfluorides, chloromethylketones, esters, boronic acids, aldehydes, arylketones, trifluoromethylketones, ketocarboxylic acids and combinations thereof.

In some embodiments, the protease-disabling moiety may be chloromethylketone and derivatives thereof.

25 In some embodiments, the alpha-amino protecting moiety may be tosyl or a derivative thereof, the peptide comprises the amino acid sequence Asp-Pro-Arg or an active variant thereof and the protease-disabling moiety may be a haloacetyl.

30 There is provided a pharmaceutical composition comprising a peptide conjugate and a pharmaceutically acceptable carrier, said peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long

derived from the C'-terminus of PAR-1 as set forth in SEQ ID NO: 17, or an active variant thereof and a protease-disabling moiety.

In some embodiments, the pharmaceutical composition may further include trichloroacetate.

5 In some embodiments, the pharmaceutical composition may further include a PAR-1 antagonist.

In some embodiments, the PAR-1 antagonist may be SCH79797 (N3-Cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine dihydrochloride).

10 There is provided use of a pharmaceutical composition comprising a peptide conjugate and a pharmaceutically acceptable carrier, said peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C'-terminus of PAR-1 as set forth in SEQ ID NO: 17, or an active variant thereof and a protease-disabling moiety, for the treatment of a disease or disorder associated
15 with excessive protease receptor activity.

In some embodiments, the protease receptor may be PAR-1.

In some embodiments, the disease or disorder may be selected from the group consisting of neuroinflammation, neuroinflammatory diseases or disorders, neurodegenerative disease or disorder, neuropathy and diabetes-related neuropathy.

20 In some embodiments, the use may be for the treatment of a tumor associated with said disease or disorder.

In some embodiments, the diseases or disorders may be selected from the group consisting of: glioma, astrocytomas, cancer, solid tumor, brain tumor, glioblastoma, oligodendroglioma, ependymoma, mixed gliomas glioblastoma multiforme, neuropathy,
25 diabetic peripheral neuropathy, Guillain-Barré syndrome, amyotrophic lateral sclerosis, acute inflammatory demyelinating polyneuropathy, acute disseminated encephalomyelitis, optic neuritis, transverse myelitis, neuromyelitis optica, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, multiple sclerosis and Parkinson's disease.

In some embodiments, the treatment may include any one or more of inhibition of the
30 progression of said disease or disorder, attenuation of the progression of said disease or disorder or prevention deterioration of said disease or disorder.

There is provided a method of treating a disease or disorder associated with excessive protease receptor activity in a patient in need of such treatment, the method comprises the step of administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising a peptide conjugate and a pharmaceutically acceptable carrier, said peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C'-terminus of PAR-1 as set forth in SEQ ID NO: 17, or an active variant thereof and a protease-disabling moiety.

In some embodiments, the pharmaceutical composition may be administered topically, intraperitoneally, systemically or intra-cranially.

In some embodiments, the treating may include any one or more of inhibiting the progression of said disease or disorder, attenuating the progression of said disease or disorder or preventing deterioration of said disease or disorder.

In some embodiments, the subject in need thereof may be a subject afflicted with said disease or disorder or a subject susceptible to said disease or disorder.

In some embodiments, the method may further comprise administering a second therapeutic agent in combination with said peptide conjugate.

In some embodiments, the second therapeutic agent may be a PAR-1 antagonist.

There is provided use of a pharmaceutical composition comprising a peptide conjugate and a pharmaceutically acceptable carrier, said peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C'-terminus of PAR-1 as set forth in SEQ ID NO: 17, or an active variant thereof and a protease-disabling moiety, for inducing a reduction in thrombin activity.

There is provided a kit for treating a disease or disorder associated with excessive protease receptor activity in a patient in need of such treatment, the kit comprises at least one container comprising a therapeutically effective amount of a pharmaceutical composition comprising a peptide conjugate and a pharmaceutically acceptable carrier, said peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C'-terminus of PAR-1 as set forth in SEQ ID NO: 17, or an active variant thereof and a protease-disabling moiety.

In some embodiments, the kit may further comprise at least one second container that includes a second therapeutic agent. In some embodiments, the second therapeutic agent may be a PAR-1 antagonist.

In some embodiments, the kit may further include instructions for use of the pharmaceutical composition for the treatment of the disease or disorder. In some embodiments, the instructions for use may include instructions for using the pharmaceutical composition in the at least one first container in combination with the pharmaceutical composition in the at least one second container. In some embodiments, the instructions may further recite a web site address providing further information, and troubleshooting among other services. In some embodiments, the instructions may be on paper form such as a package insert or label.

Further embodiments and the full scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows mean thrombin-like activity (U/ml $\pm$ SEM) in sciatic nerves of (A) EAN rats at day of induction and at 10, 14 and 19 days post induction (EAN 10, n=10; EAN14, n=10; EAN19, n=10, respectively) vs. control rats (n=10) and CFA (complete Freund's adjuvant) mice; and in (B) STZ rats (n=15) vs. control rats (n=12) (**= p<0.01; *= p<0.005).

Figure 2 shows Western blots (A, C) and the corresponding statistical analyses (B, D) from 3 independent experiments of PAR-1 immunoreactivity (A, B) and PN-1 immunoreactivity (C, D) in desheathed sciatic nerve from STZ-induced diabetic rats (n=3) and control non-diabetic rats (n=3; *=p<0.05; **= p<0.01).

Figure 3 presents the effect of (i) N alpha-tosyl-L-lysine chloromethyl ketone (TLCK, 4.4 mg/kg, n=5) and (ii) N α -(2-naphthyl-sulphonyl-glycyl)-DL-p-amidinophenylalanyl-piperidine (NAPAP, NAPAP-120 μ M/ kg body weight, n=5), treatments (black bars) relative to control/CFA (grey bars, n=3) and relative to EAN untreated rats (EAN, n=5) through electrophysiological tests: latency (A), conduction velocity (B) and amplitude (C). Statistics are indicated as follows: *= p<0.05, **= p<0.01.

Figure 4 shows the effect of N alpha-tosyl-L-lysine chloromethyl ketone (TLCK, 4.4 mg/kg body weight, n=8) and (ii) N α -(2-naphthyl-sulphonyl-glycyl)-DL-p-amidinophenylalanyl-piperidine (NAPAP, 120 μ M/ kg body weight, n=5), treatments (black bars) relative to control

(grey bars, n=4) and STZ-induced diabetic untreated rats (n=5) through electrophysiological tests: latency (A), conduction velocity (B) and amplitude (C). *= p<0.05, **= p<0.01.

Figure 5 exhibits Western blots of PAR-1 and actin (A) and a corresponding statistical analysis (B) in brain homogenates derived from SOD-1 and wild-type control mice (p<0.001).

5 **Figure 6** exhibits a Kaplan-Meier survival curve of (full diamond) untreated (control) SOD-1 mice, (empty circle) SOD-1 mice treated with TLCK (4.4 mg/kg), and (empty triangle) mice treated with PAR-1 antagonist (SCH79797; 25 µg/kg).

Figure 7 exhibits the Thrombin-like activity before (black bars) and after treatment with NAPAP (grey bars) in C6 (A) and CNS-1 (B) glioma cells and their surrounding medium.

10 **Figure 8A** exhibits proliferation of C6 control cells (black bar) and cells treated with various doses of PAR-1 antagonist SCH79797 (grey bars).

Figure 8B shows proliferation of CNS-1 control cells (black bar) and cells treated with each of PAR-1 antagonists: SCH79797, NAPAP and TLCK, and combinations thereof (grey bars).

15 **Figure 9** exhibits proliferation of CNS-1 glioma cell-line upon dose-dependent treatment with TLCK (grey bars) compared to non-treated cells (black bar).

Figure 10 presents the effect of the various doses of the peptide conjugates encompassing the peptide Asp-Pro-Arg (short peptide; 3AA) and the peptide set forth in SEQ ID NO: 4 (long peptide; 7AA) on proliferation of CNS-1 glioma cell-line (grey bars) relative to control (non-treated cells black bar).

20 **Figure 11** presents dose-dependent inhibition of glioma proliferation by different concentrations of the peptide conjugates encompassing the peptide Asp-Pro-Arg and the peptides of SEQ ID NOs: 2-4 (11A-11D, respectively) after 48 h.

25 **Figure 12** presents dose-dependent inhibition of glioma proliferation by different concentrations of the peptide conjugates encompassing the peptide Asp-Pro-Arg and the peptides of SEQ ID NOs: 2-4 (12A-12D, respectively) after 72 h.

Figure 13 presents the effect of the peptide conjugates encompassing the peptide set forth in SEQ ID NO: 4 (7AA) with or without PAR-1 antagonist (1µM) on proliferation (XTT) of CNS-1 glioma cell-line (grey bars) compared to untreated cells (control; black bar).

30 **Figure 14** presents thrombin-like activity in thrombin inhibition assay under various doses of the peptide conjugates (from 156 nanomolar to 1mM to) encompassing the peptide Asp-Pro-

Arg (3AA; A) and the peptide set forth in SEQ ID NO: 4 (7AA; B) relative to control (i.e. without the presence of any of the peptide conjugates (diamonds)).

Figure 15 presents thrombin activity (ratio) performed in a thrombin activity assay (non-cellular) under different concentrations of the peptide conjugates encompassing the peptide Asp-Pro-Arg (3AA; x, grey line) or the peptides set forth in SEQ ID NO: 1 (4AA; x, dark line); SEQ ID NO: 2 (5AA, triangle, dark line); SEQ ID NO: 3 (6AA; square, grey line) and SEQ ID NO: 4 (7AA; diamond, dark line).

Figure 16 presents the effect of the various doses of the peptide conjugates encompassing the peptide Asp-Pro-Arg (3AA) and the peptide set forth SEQ ID NO: 4 (7AA) on thrombin-like activity in CNS-1 glioma cell-line (grey bars) compared to untreated cells (control; black bar).

Figure 17 presents thrombin activity (ratio) generated by rat glioma cells inhibited by different concentrations of the peptide conjugates encompassing the peptide Asp-Pro-Arg (3AA; asterisk) or the peptides set forth in SEQ ID NO: 1 (4AA; x); SEQ ID NO: 2 (5AA; triangle); SEQ ID NO: 3 (6AA; square) and SEQ ID NO: 4 (7AA; diamond).

Figure 18 presents thrombin activity in plasma samples after addition of the peptide conjugates encompassing the peptide Asp-Pro-Arg (A) or the peptides set forth in SEQ ID NO: 2 (B); SEQ ID NO: 3 (C); and SEQ ID NO: 4 (D).

Figure 19 presents sciatic nerve conduction velocity (m/s) in a Diabetes melitus mice model (induced by streptozotocin (STZ) injection) untreated (STZ) or treated with T6AACK (a peptide conjugate encompassing the peptide 6AA (SEQ ID NO: 3) nested between tosyl and CK) at different concentrations and compared to normal mice without diabetes (Control).

Figure 20 presents changes in tumor size (A) and in the size of edema surrounding the tumor (B) in 3 groups of rats: (1) control; (2) treatment with 2 μ M of a peptide conjugate comprising the peptide termed 6AA (SEQ ID NO: 3); and (3) treatment with 20 μ M of a peptide conjugate comprising the peptide termed 6AA (SEQ ID NO: 3).

Figure 21 presents the percentage survival of rats in the following treatment groups: control (saline; circle), 2 μ M of a peptide conjugate comprising the peptide termed 6AA (SEQ ID NO: 3; square), and 20 μ M of a peptide conjugate comprising the peptide termed 6AA (SEQ ID NO: 3; diamond).

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel peptide conjugates that target an increased protease activity associated with diseases and disorders by specifically protecting PAR receptors from being over-activated.

It has long been recognized that in PAR-1 (NP_001983.2) the extracellular fragment
5 (amino-terminal exodomain) carries all determinants for thrombin recognition. In some embodiments, the sequence of said amino-terminal exodomain is as follows: ³⁸LDPRSFLLRNPNDKYEPF⁵⁵ (SEQ ID NO: 18). This peptide sequence is bridging thrombin active site and exosite I. Furthermore, the sequence ³⁸LDPR⁴¹ (also termed LDPR; SEQ ID NO: 1), is contacting the thrombin active site and the acidic hirudin-like motif, ⁵¹KYEPF⁵⁵ (SEQ ID
10 NO: 19), thereby engaging thrombin exosite I. Although the highest binding affinity and maximal proximity was found between ³⁸LDPR⁴¹ (P1 to P4; (SEQ ID NO: 1) and the active site of thrombin, a 3D modeling of PAR-1 N-terminal peptide and thrombin reveals contacts (with lower strength) up to amino acid at position 20 (P20). PAR-1 activation requires specific binding of thrombin and similar proteases to a binding site on the receptor, which is just
15 preceding the cleavage site. The binding site on the receptor PAR-1 comprises the amino acid sequence PESKATNATLDPR (SEQ ID NO: 10) that is significantly different from the equivalent sequences in PAR-2, 3 and 4. As exemplified in Table 2, hereinbelow, there is a high degree of homology between the human, mouse, rat and bovine PAR-1 in positions P1 to P7, wherein the highest homology is at P1-P2 and P5-P7.

20 In the nervous system a major factor is played by the activation of PARs on glia cells. In the peripheral nervous system (PNS), PAR-1 is localized to the non-compacted myelin of Schwann cells at the node of Ranvier, and in the neuromuscular junction it is localized to the peri-synaptic glia and the post-synaptic muscle. The inventors of the present invention were the first to show a functional role for PAR-1 activation on the glia component of the node of Ranvier
25 in the PNS where activation of the receptor caused nerve conduction block (Shavit et al., Brain, 2008, vol. 131(Pt 4): p. 1113-1122). In the central nervous system (CNS) PAR-1 was found on neurons and glia. It was suggested that PAR-1 is localized to a specific astrocyte structure at the synapse, and the inventors of the present invention have confirmed this location by high resolution methods such as confocal and electron microscopy (Shavit et al., J Neurochem.
30 119(3): p. 460-473). PAR-1 activation was shown to hold a physiological role at the CNS synapse where its activation modulates synaptic transmission by causing long-term potentiation (LTP) and seizure-like activity and potentiates the synaptic N-methyl-D-aspartate (NMDA) receptor. It is interesting to note therefore that PAR-1 is a marker of glial structures adjacent to

the most physiologically active parts of the nervous system, the synapse and the node of Ranvier.

Thus, there is provided a peptide conjugate comprising a protecting moiety, a peptide comprising the amino acid sequence DPR (also termed Asp-Pro-Arg) or an active variant thereof and a thrombin-disabling moiety.

In some embodiments, the peptide conjugate may comprise the following structure: PRO-PEP-DIS, wherein PRO is a protecting moiety, such as, an alpha-amino protecting moiety; PEP is a peptide moiety comprising the amino acid sequences DPR or amino acid sequences comprising same, as set forth in SEQ ID NO:2 to SEQ ID NO:17, or an active variant thereof; and DIS may be a protease-disabling moiety, wherein PRO may be bound to the N'-terminus amino acid of PEP directly or via a linker, and wherein DIS may be bound to the C'-terminus amino-acid of PEP directly or via a linker. Each possibility represents a separate embodiment of the present invention.

The terms "peptide moiety" and "PEP" are interchangeable and refer to a peptide moiety derived from the PAR-1, including, but not limited to, the C'-terminus of PAR-1 (SEQ ID NO: 17).

In some embodiments, the peptide moiety may have an amino-acid sequence at least 3 amino acid long derived from the C'-terminus of PAR-1.

In some embodiments, the peptide moiety may have an amino-acid sequence at least 3 amino-acid long and at most 7 amino-acid long, derived from the C'-terminus of PAR-1.

In some embodiments, the peptide moiety may have an amino-acid sequence of at least 3 amino-acid long and at most 7 amino-acid long derived from the C'-terminus of PAR-1 starting from Arginine at position 20 and continuing towards the N'-terminus.

In some embodiments, the amino-acid sequences of DPR and SEQ ID NO: 1 to SEQ ID NO:17 are fragments of the PAR-1 receptor, to which thrombin binds and the peptide conjugates of the present invention comprise such sequence as decoy for thrombin i.e. to enable their specific binding to thrombin.

In some embodiments, the peptide moiety comprises an amino-acid sequence selected from the group consisting of DPR, LDPR (SEQ ID NO: 1), TLDPR (SEQ ID NO: 2), ATLDPR (SEQ ID NO: 3), NATLDPR (SEQ ID NO: 4), TNATLDPR (SEQ ID NO: 5), ATNATLDPR (SEQ ID NO: 6), KATNATLDPR (SEQ ID NO: 7), SKATNATLDPR (SEQ ID NO: 8), ESKATNATLDPR (SEQ ID NO: 9), PESKATNATLDPR (SEQ ID NO: 10),

RPESKATNATLDPR (SEQ ID NO: 11), RRPESKATNATLDPR (SEQ ID NO: 12),
ARRPESKATNATLDPR (SEQ ID NO: 13), RARRPESKATNATLDPR (SEQ ID NO: 14),
TRARRPESKATNATLDPR (SEQ ID NO: 15), RTRARRPESKATNATLDPR (SEQ ID NO:
16) and ARTRARRPESKATNATLDPR (SEQ ID NO: 17). Each possibility represents a
5 separate embodiment of the present invention.

In some embodiments, the peptide moiety may consist of Asp-Pro-Arg (DPR). In some
embodiments, the peptide moiety may consist of SEQ ID NO: 1. In some embodiments, the
peptide moiety may consist of SEQ ID NO: 2. In some embodiments, the peptide moiety may
consist of SEQ ID NO: 3. In some embodiments, the peptide moiety may consist of SEQ ID
10 NO: 4. In some embodiments, the peptide moiety may consist of SEQ ID NO: 5. In some
embodiments, the peptide moiety may consist of SEQ ID NO: 6. In some embodiments, the
peptide moiety may consist of SEQ ID NO: 7. In some embodiments, the peptide moiety may
consist of SEQ ID NO: 8. In some embodiments, the peptide moiety may consist of SEQ ID
NO: 9. In some embodiments, the peptide moiety may consist of SEQ ID NO: 10. In some
15 embodiments, the peptide moiety may consist of SEQ ID NO: 11. In some embodiments, the
peptide moiety may consist of SEQ ID NO: 12. In some embodiments, the peptide moiety may
consist of SEQ ID NO: 13. In some embodiments, the peptide moiety may consist of SEQ ID
NO: 14. In some embodiments, the peptide moiety may consist of SEQ ID NO: 15. In some
embodiments, the peptide moiety may consist of SEQ ID NO: 16. In some embodiments, the
20 peptide moiety may consist of SEQ ID NO: 17.

In some embodiments, the peptide moiety may comprise an amino-acid sequence Asp-
Pro-Arg or an active variant thereof. In some embodiments, the peptide moiety may comprise
an amino-acid sequence set forth in SEQ ID NO: 1 or an active variant thereof. In some
embodiments, the peptide moiety may comprise an amino-acid sequence set forth in SEQ ID
25 NO: 2 or an active variant thereof. In some embodiments, the peptide moiety may comprise an
amino-acid sequence set forth in SEQ ID NO: 3 or an active variant thereof. In some
embodiments, the peptide moiety may comprise an amino-acid sequence set forth in SEQ ID
NO: 4 or an active variant thereof. In some embodiments, the peptide moiety may comprise an
amino-acid sequence set forth in SEQ ID NO: 5 or an active variant thereof. In some
30 embodiments, the peptide moiety may comprise an amino-acid sequence set forth in SEQ ID
NO: 6 or an active variant thereof. In some embodiments, the peptide moiety may comprise an
amino-acid sequence set forth in SEQ ID NO: 7 or an active variant thereof. In some
embodiments, the peptide moiety may comprise an amino-acid sequence set forth in SEQ ID
NO: 8 or an active variant thereof. In some embodiments, the peptide moiety may comprise an

amino-acid sequence set forth in SEQ ID NO: 9 or an active variant thereof. In some embodiments, the peptide moiety may comprise an amino-acid sequence set forth in SEQ ID NO: 10 or an active variant thereof. In some embodiments, the peptide moiety may comprise an amino-acid sequence set forth in SEQ ID NO: 11 or an active variant thereof. In some
5 embodiments, the peptide moiety may comprise an amino-acid sequence set forth in SEQ ID NO: 12 or an active variant thereof. In some embodiments, the peptide moiety may comprise an amino-acid sequence set forth in SEQ ID NO: 13 or an active variant thereof. In some embodiments, the peptide moiety may comprise an amino-acid sequence set forth in SEQ ID NO: 14 or an active variant thereof. In some embodiments, the peptide moiety may comprise
10 an amino-acid sequence set forth in SEQ ID NO: 15 or an active variant thereof. In some embodiments, the peptide moiety may comprise an amino-acid sequence set forth in SEQ ID NO: 16 or an active variant thereof. In some embodiments, the peptide moiety may comprise an amino-acid sequence set forth in SEQ ID NO: 17 or an active variant thereof.

The terms "active variant", "analogue" and "variant" as used herein are interchangeable
15 and refer to any peptide moiety derived from a peptide sequence as set forth in DPR and any one of SEQ ID NO:1 to SEQ ID NO:17 by at least one amino-acid substitution, that retains at least 70%, optionally, at least 80% or at least 90% or at least 95%, of the biological activity of the sequence from which it was derived, or to which it is most similar to. These terms also encompass peptides comprising regions having substantial similarity to the peptide moiety,
20 such as structural variants.

The term "substantial similarity" means that two peptide sequences, when optimally aligned, share at least 50 percent sequence identity, at least 60 percent sequence identity, at least 70 percent sequence identity, at least 80 percent sequence identity, at least 90 percent sequence identity, or at least 95 percent sequence identity or more (e.g., 99 percent sequence
25 identity). Typically, residue positions, which are not identical, differ by conservative amino acid substitutions.

In some embodiments, one or more of the peptide moieties may correspond to variants of the amino-acid sequence DPR or the amino acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:17. Each possibility represents a separate embodiment of the present invention.

30 In some embodiments, said variants may comprise conservative substitutions relative to the amino acid sequence of the peptide moiety corresponding thereto.

Examples of conservative substitutions as considered in the present invention are the substitution of any positive-charge amino-acid (Arg, His, Lys) with any other positive-charge

amino-acid; the substitution of any negative-charge amino-acid (Asp, Glu) with any other negative-charge amino-acid; the substitution of any polar-uncharged amino-acid (Ser, Thr, Asn, Gln) with any other polar-uncharged amino-acid; or the substitution of any hydrophobic amino-acid (Ala, Ile, Leu, Met, Phe, Trp, Tyr, Val) with any other hydrophobic amino-acid.

5 Thus, in some embodiments, active variant may comprise Arg/His/Lys substitution; Asp/Glu substitution; Ser/Thr/Asn/Gln substitution; Ala/Ile/Leu/Met/Phe/Trp/Tyr/Val substitution; or any combination of the above. Each possibility represents a separate embodiment of the present invention.

10 In some embodiments, the peptide may be selected from the amino-acid sequences DPR and those set forth in SEQ ID NOs: 1 to 17, wherein at least on proline is substituted with a positive-charge amino acid. In other embodiments, the peptide is selected from DPR and SEQ ID NOs: 1 to 17, wherein at least on proline is substituted with lysine. Without being bound by any theory of mechanism, the peptide is substituted in order to obtain improved specificity to thrombin and potentially other coagulation factors, improved penetration into the brain and
15 prolonged half-life of the conjugate.

Residue positions, which are not identical, may also be composed of peptide analogs, including unnatural amino acids or derivatives of such. Analogs typically differ from naturally occurring peptides at one, two or a few positions, often by virtue of conservative substitutions.

20 Some analogs may also include unnatural amino acids or modifications of N or C terminal amino acids at one, two or a few positions. Examples of unnatural amino acids, without limiting to, are D-amino acids, alpha, alpha-disubstituted amino acids, N-alkyl amino acids, lactic acid, 4-hydroxyproline, gamma-carboxyglutamate, epsilon-N,N,N-tri methyllysine, epsilon-N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, omega-N-methylarginine, and isoaspartic acid.

25 The terms "protecting moiety" and "PRO" are interchangeable and refer to any moiety capable of protecting the peptide conjugate of the present invention from adverse effects such as proteolysis, degradation or clearance, or alleviating such adverse effects.

In some embodiments, the protecting moiety may be an alpha-amino protecting moiety. In some embodiments, the protecting moiety may be tosyl (a tosyl group) or derivatives thereof.

30 In some embodiments, the alpha-amino protecting moiety may be tosyl.

In some embodiments the protecting moiety is selected from the group consisting of t-butyloxycarbonyl (BOC, (CH₃)₃COCO-, t-BOC), t-amylloxycarbonyl, adamantyl-oxycarbonyl,

and p-methoxybenzyloxycarbonyl, 9-fluorenylmethoxycarbonyl (Fmoc), 2-chlorobenzyloxycarbonyl and the like, nitro, tosyl ($\text{CH}_3\text{C}_6\text{H}_4\text{SO}_2-$), benzyloxycarbonyl (CBZ), adamantyloxycarbonyl, 2,2,5,7,8-pentamethylchroman-6-sulfonyl, 2,3,6-trimethyl-4-methoxyphenylsulfonyl, t-butyl benzyl (BZL) or substituted BZL, such as, p-methoxybenzyl, 5 p-nitrobenzyl, p-chlorobenzyl, o-chlorobenzyl, and 2,6-dichlorobenzyl. Each possibility represents a separate embodiment of the present invention.

In some embodiments, PRO may be selected from t-butyl, cyclohexyl, cyclopentyl, benzyloxymethyl (BOM), tetrahydropyranyl, trityl, chlorobenzyl, 4-bromobenzyl, and 2,6-dichlorobenzyl. Each possibility represents a separate embodiment of the present invention.

10 Other protecting groups which may suitably employed are bromobenzyloxycarbonyl, xanthyl (Xan) and p-methoxybenzyl. Each possibility represents a separate embodiment of the present invention.

In some embodiments, PRO may be tosyl.

The terms "protease-disabling moiety" and "DIS" as used herein are interchangeable 15 and refer to any moiety capable of binding to a protease and transiently or permanently disabling its proteolytic activity. In some embodiments, the protease-disabling moiety may be a thrombin-disabling moiety. In some embodiments, the protease disabling moiety may be a thrombin inhibitor.

In some embodiments, the protease-disabling moiety may be a protease-disabling 20 compound selected from irreversible inhibitors and reversible inhibitors.

In some embodiments, the protease-disabling moiety may be an irreversible inhibitor selected from the group consisting of substituted acetyl (1-x-actyl), sulfonylfluorides ($-\text{SO}_2\text{F}$), chloromethylketones ($-\text{COCH}_2\text{Cl}$), esters ($-\text{COOR}$), boronic acids ($-\text{B}(\text{OR})_2$) and combinations thereof.

25 In some embodiments, the protease-disabling moiety may be a reversible inhibitor selected from the group consisting of aldehydes ($-\text{CHO}$), arylketones ($-\text{CO-Aryl}$), trifluoromethylketones ($-\text{COCF}_3$) ketocarboxylic acids ($-\text{COCOOH}$) and combinations thereof.

In some embodiments the protease-disabling moiety may be a protease-disabling 30 compound selected from the group consisting of chloromethylketone (CK) and derivatives thereof, sulfonylfluorides ($-\text{SO}_2\text{F}$), chloromethylketones ($-\text{COCH}_2\text{Cl}$), esters ($-\text{COOR}$), boronic acids ($-\text{B}(\text{OR})_2$), aldehydes ($-\text{CHO}$), arylketones ($-\text{CO-Aryl}$), trifluoromethylketones ($-\text{COCF}_3$) and ketocarboxylic acids ($-\text{COCOOH}$).

In some embodiments, the protease-disabling moiety may be a substituted acetyl. In some embodiments, the substituted acetyl may be haloacetyl. In some embodiments, the haloacetyl may be chloroacetyl. In some embodiments, the protease-disabling moiety may be chloromethylketone (CK).

5 In some embodiments, the peptide conjugate may be tosyl-DPR-CK. In some embodiments, the peptide conjugate may be tosyl-LDPR-CK. In some embodiments, the peptide conjugate may be tosyl-TLDPR-CK. In some embodiments, the peptide conjugate may be tosyl-ATLDPR-CK. In some embodiments, the peptide conjugate may be tosyl-NATLDPR-CK.

10 In some embodiments, the peptide conjugate may be tosyl-PEP-CK, wherein PEP is Aspartic acid-Proline-Arginine or any one of the peptides set forth in SEQ ID NOs: 1-17, or an active variant thereof, wherein CK may be bound to the C'-terminus amino-acid of Arginine and tosyl may be bound to the N'-terminus amino acid of PEP.

Several thrombin inhibitors are known in the art, including T-L-C-K (also known as N
15 alpha-tosyl-L-lysine chloromethyl ketone or TLCK), NAPAP (also known as N α -(2-naphthylsulphonyl-glycyl)-DL-p-amidinophenylalanyl-piperidine), PN-1 (also known as Protease nexin-1), PN-2 (also known as Protease nexin-2, APP) and SCH79797 (also known as N3-Cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine dihydrochloride). TLCK is an irreversible inhibitor of the serine protease trypsin (inactivates
20 trypsin most rapidly at pH 7.5), and many trypsin-like serine proteases. The histidine-46 residue located in the active site of trypsin is alkylated by TLCK. NAPAP binds thrombin in the S1, S2 and S4 pockets. The amidine group on NAPAP forms a bidentate salt-bridge with Asp deep in the S1 pocket, the piperidine group takes the role of proline residue and binds in the S2 pocket, and the naphthyl rings of the molecule forms a hydrophobic interaction with Trp in the S4
25 pocket. PN-1 is a 43 kDa thrombin inhibitor, member of the serine protease inhibitor superfamily (serpins), which regulates matrix accumulation and coagulation under pathophysiologic conditions by inhibiting thrombin, plasmin, and tissue plasminogen activators. PN-2 is a protease inhibitor, which is the secreted form of the amyloid beta-protein precursor (APP) which contains a Kunitz protease inhibitor domain. SCH79797 is a potent and
30 selective non-peptide antagonist of protease activated receptor-1 (PAR-1).

However, the alleged therapeutic effect of the known inhibitors is accompanied by serious adverse effects. For example, as detailed below, the very short peptide T-L-C-K, induced inhibition of glioma-cell proliferation, at relatively high concentrations (mM) but caused severe internal bleeding.

Surprisingly, the peptide conjugates of the invention, which are based on the thrombin binding site on PAR-1, provide the required therapeutic effect without causing mortal side effect. As exemplified hereinbelow, the peptide conjugates were shown to effectively inhibit glioma growth and thrombin activity.

5 In some embodiments, the N' terminal amino acid of PEP may covalently bind to PRO, directly or via a linker, through its N' amino-group or through its side-chain. In some embodiments, the C' terminal amino acid of PEP may covalently bind to DIS, directly or via a linker, through its C' carboxyl-group or through its side-chain.

In some embodiments, PRO may be bound to PEP via a linker.

10 The term "linker" as used herein refers to any molecule bound to both PRO and PEP and/or to both PEP and DIS. In its simplest form, a linker may be a covalent bond. More elaborate linkers may be amino-acid moieties, peptide moieties, nucleotide moieties, oligonucleotide moieties etc. Contemplated linkers may also serve a further therapeutic purpose, for example, they may be fluorescent, thereby enabling detection of the peptide
15 conjugates carrying them, or they may be a polyethylene glycol (PEG) moiety, further protecting the peptide conjugates carrying them from degradation. Thus, in some embodiments, said linker may be selected from the group consisting of a peptide linker and an oligonucleotide linker. Each possibility represents a separate embodiment of the present invention.

In some embodiments, there is provided a pharmaceutical composition, comprising the
20 peptide conjugate described above, as a pharmaceutically active ingredient, and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition may further comprises trichloroacetate (TCA) salt.

The term "pharmaceutically acceptable carrier" as used herein refers to any of the standard pharmaceutical carriers known in the field such as sterile solutions, tablets, coated
25 tablets, and capsules. Typically, such carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acids or salts thereof, magnesium or calcium stearate, talc, vegetable fats or oils, gums, glycols, or other known excipients. Such carriers may also include flavor and color additives or other ingredients.

Examples of pharmaceutically acceptable carriers include, but are not limited to, the
30 following: water, saline, buffers, inert, nontoxic solids (e.g., mannitol, talc).

Compositions comprising such carriers are formulated by well-known conventional methods. Depending on the intended mode of administration and the intended use, the compositions may be in the form of solid, semi-solid, or liquid dosage forms, such, for example,

as powders, granules, crystals, liquids, suspensions, liposomes, nano-particles, nano-emulsions, pastes, creams, salves, etc., and may be in unit-dosage forms suitable for administration of relatively precise dosages.

5 In some embodiments, the pharmaceutical composition of the invention may be formulated for oral, nasal, aerosol, inhalational, abdominal, subcutaneous, intra-peritoneal or intravenous administration. Each possibility represents a separate embodiment of the present invention.

In some embodiments, the pharmaceutical composition of the invention may be for intravenous administration.

10 In some embodiments, there is provided use of a peptide conjugate as described above, for the treatment of a disease or disorder associated with excessive protease activity.

In some embodiments, the use of the peptide conjugate may further include use of a second therapeutic agent. In some embodiments, the second therapeutic agent may be a PAR-1 antagonist.

15 As used herein, the term 'excessive protease activity' refers to activity which is at least twice as high as normal activity of the protease. In some embodiments, excessive protease activity refers to an activity that is at least three times higher the normal activity of the protease. For example, typical excess activity of protease in stroke, diabetes, ALS, EAE, trauma and glioma is two to three times higher than the protease activity in control subjects. In another
20 example, the excess activity in stroke is up to 100 times higher than the protease activity in control subjects.

The term "disease or disorder associated with excessive protease activity" as used herein refers to any disease or disorder known to be caused and/or manifested by a higher than normal protease activity, as determined by standard methods well known in the art.

25 In some embodiments, there is provided a method for treating a disease or disorder associated with excessive protease receptor activity comprising administering to a subject in need thereof, a pharmaceutical composition comprising a peptide conjugate according to the present invention and a carrier,

30 In some embodiments, said disease or disorder may be selected from the group consisting of neuroinflammation, neuroinflammatory diseases or disorders, neurodegenerative disease or disorder, neuropathy, and diabetes-related neuropathy. Each possibility represents a separate embodiment of the present invention.

Diabetic peripheral neuropathy (DPN), one of the most prevalent forms of diabetes-related neuropathy, principally manifests itself as sensory loss and weakness of the lower limbs and ultimately accounts for significant morbidity contributing to amputation. In the PNS the prototypical inflammatory disease affecting nerve cells is the Guillain-Barré syndrome (GBS).

5 GBS is a group of acute inflammatory neuropathies and its animal model is experimental autoimmune neuritis (EAN). Acute inflammatory demyelinating polyneuropathy (AIDP) is the most common form of GBS, and is characterized by demyelination of peripheral axons and axonal degeneration in severe cases. The mechanism leading to GBS are still being elucidated and most of the evidence points to an immune attack at the node of Ranvier including the glial
10 components. Amyotrophic lateral sclerosis (ALS) also affects peripheral nerve by causing selective degeneration of lower motor nerves together with degeneration of upper motor neurons in the brain. The cause of this disease is not known and treatment for it is limited to the use of riluzol, a glutamate receptor antagonist, which is only partially effective and patients with this disease will die within 2 years of diagnosis.

15 In some embodiments, said diseases or disorders may be selected from the group consisting of: glioma, astrocytomas, glioblastoma, oligodendroglioma, ependymoma, mixed gliomas glioblastoma multiforme, neuropathy, diabetic peripheral neuropathy, Guillain-Barré syndrome, amyotrophic lateral sclerosis, acute inflammatory demyelinating polyneuropathy, acute disseminated encephalomyelitis, optic neuritis, transverse myelitis, neuromyelitis optica,
20 Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, multiple sclerosis and Parkinson's disease. Each possibility represents a separate embodiment of the present invention.

In some embodiments, treating may include any one or more of inhibiting the progression of said disease or disorder, attenuating the progression of said disease or disorder
25 or preventing deterioration of said disease or disorder. Each possibility represents a separate embodiment of the present invention.

In some embodiments, there is provided use of a peptide conjugate described above, for the preparation of a medicament for the treatment of a disease or disorder associated with excessive protease receptor activity. Each possibility represents a separate embodiment of the
30 present invention.

In some embodiments, there is provided a method of treating a disease or disorder associated with excessive protease receptor activity in a patient in need of such treatment, comprising administering a therapeutically effective amount of the pharmaceutical composition

described above to said patient, thereby treating said disease or disorder. Each possibility represents a separate embodiment of the present invention.

In some embodiments, the method of treating the disease or disorder may further include administering a second therapeutic agent. In some embodiments, the second therapeutic agent
5 may be a PAR-1 antagonist.

There is provided a kit comprising a peptide conjugate for the treatment of a disease or disorder associated with excessive protease receptor activity, wherein the peptide conjugate may be as set forth in formula I:

(I) PRO-PEP-DIS

10 wherein, PRO is a protecting moiety; PEP is a peptide moiety comprising Aspartic acid-Proline-Arginine, or an active variant thereof; and DIS is a protease-disabling moiety, and wherein PRO is bound to the N'-terminus amino acid of PEP directly or via a linker, and wherein DIS is bound to the C'-terminus amino acid of PEP directly or via a linker.

In some embodiments, the kit may further include instructions for use of the
15 pharmaceutical composition for the treatment of the disease or disorder. In some embodiments, the instructions may further recite a web site address providing further information, and troubleshooting among other services. In some embodiments, the instructions may be on paper form such as a package insert or label.

In some embodiments, the methods of the invention are aimed at preventing excessive
20 protease receptor activity, including, preventing the onset of excessive protease receptor activity. Determining the dose of the peptide conjugate required for preventing protease receptor activity may be carried out by assessing reduction in the PAR-1 levels following administration of the peptide conjugate of the invention. Reduction in excessive protease receptor activity refers to a decrease in, or an absence of, activity of the receptor relative to the
25 levels of activity prior to administration or relative to a control value. Reduced PAR-1 activity, includes reduction of activity by at least about 10% (e.g., 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%), as compared to the level of activity just prior to administration. Hence, the level of activity obtained from a sample of a patient in need thereof may be compared to the level of PAR-1 activity in a sample obtained from said patient in previous time points (e.g., prior to
30 administration of the peptide conjugate or during the onset of a neuropathic disease or disorder). It is further optional to measure PAR-1 activity in an individual prior to the onset of a disease or disorder (e.g., during a regular check-up), in order to determine the individual's baseline.

The PAR-1 activity in a patient in need thereof may be compared to a standard or control obtained from normal individuals. In one example, PAR-1 activity can be assessed in a population of healthy individuals or individuals who have not had a neuropathic disease or disorder. Such activity is referred to as a "negative control." Conversely, PAR-1 may also be
5 obtained from a pool of individuals who are undergoing a neuroinflammation, neuroinflammatory diseases or disorders, neurodegenerative disease or disorder, neuropathy, or diabetes-related neuropathy, in order to obtain a "positive control." Thus, in some embodiments, following administration of the peptide conjugate of the invention, the activity level of PAR-1 may decrease; the level(s) may get closer to the level of the negative control,
10 and farther from the positive control. Alternatively, the PAR-1 levels of activity decrease as compared to the levels during the onset of the aforementioned disease or disorder.

The terms "comprises", "comprising", "includes", "including", "having" and their conjugates mean "including but not limited to". This term encompasses the terms "consisting of" and "consisting essentially of". As used herein, the singular form "a", "an", "the" and "said"
15 include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.

The following examples are presented in order to more fully illustrate some embodiments of the invention. They should, in no way be construed, however, as limiting the broad scope of
20 the invention. One skilled in the art can readily devise many variations and modifications of the principles disclosed herein without departing from the scope of the invention.

EXAMPLES

Example 1. Thrombin-like activity in sciatic nerves of diabetic rats

25 Thrombin-like activity was measured in sciatic nerves derived from animal models of Guillain-Barré Syndrome (termed EAN, for experimental autoimmune neuritis; Fig. 1A) and diabetes (streptozotocine (STZ)-induced diabetes; Fig. 1B).

As presented in Figure 1 the soluble thrombin-like activity generated by, and released from, sciatic nerves of EAN or diabetic (STZ) rats, into the surrounding medium, was compared
30 to thrombin-like activity in healthy control rats (n=12) and in CFA mice (complete Freund's adjuvant). The latter control group refers to mice treated with an inoculum containing the mycobacterium tuberculosis emulsified in saline and CFA only. The results indicate that

thrombin-like activities were significantly elevated in EAN rats 10 days after induction (Data is presented as a mean thrombin like activity U/ml $\pm$ SEM, **= $p<0.01$; *= $p<0.005$).

The results further indicate that thrombin-like activities were significantly elevated in diabetic rats (Figure 1B, **= $p=0.00071$).

5 The conduction velocity of sciatic nerves derived from an animal model of diabetes (streptozotocine (STZ)-induced diabetes; Fig. 20) was measured in mice treated daily with sham (STZ), or with the active drug ATLDPR (peptide 6AA; SEQ ID NO: 3) nested between N alpha-tosyl and chloromethyl ketone, namely TTN-ATLDPR-CK (termed hereinafter T6AACK; SEQ ID NO:20) injected in 100 microliter of 10 nM, 100nM and 1 micromolar.

10 Conduction velocities in the sciatic nerves of the mice were assessed by standard electrophysiology nerve conduction methods by a blind assessor. The nerve conduction studies were carried out one month after the induction of diabetes. A group of normal mice without diabetes served as controls. All STZ treated mice developed severe diabetes.

15 The comparison of sham treated and T6AACK 1 micromolar treated mice was highly significant, resulting with $p=0.00046$ (T-test) and the effect of the 10 nM dose followed a similar trend, resulting with $p=0.016$ (Fig. 20).

Thus, elevated thrombin-like activity in diabetic rats represents a potential target for intervention by the new conjugates of the present invention.

Example 2. PAR-1 expression level in sciatic nerves of diabetic rats

20 The expression level of PAR-1 was measured in desheathed sciatic nerves from STZ-induced diabetic rats and control non-diabetic rats (Fig. 2A-2B).

25 Western blot analysis of PAR-1 level from sciatic nerves of two STZ-induced rats, as compared to two healthy controls indicates a significant decrease in PAR-1 level in STZ-induced rats sciatic-nerves ($n=3$; $p=0.012$) compared to control non-diabetic rats (Fig. 2B; data presented as a mean fold $\pm$ SEM, *= $p<0.05$).

30 Based on Figure 2 and further data (not disclosed) significantly low levels of PAR-1 are found in the animal models of Guillain-Barré Syndrome (EAN) and diabetes (STZ-induced diabetic rats). Without being bound by any theory or mechanism, such findings may indicate an intrinsic protection mechanism employed by the nerves to avoid PAR-1 over activation by the elevated thrombin-like activities (such as presented in Figure 1B). Thus, PAR-1 sensitivity may strengthen the need to interfere with the PAR-1 pathway and protect the receptor from over-activation.

Example 3. PN-1 expression level in sciatic nerves of diabetic rats

The expression level of PN-1 (thrombin-inhibitor, 143 kDa) was measured in desheathed sciatic nerves from STZ-induced diabetic rats and control non-diabetic rats, by Western blot analysis (Figs. 3A-3B).

5 The result show a significant increase in PN-1 level in STZ-induced rats sciatic-nerves (p=0.003) compared to control non-diabetic rats (Fig. 3B; data presented as a mean fold $\pm$ SEM, ** = p<0.01).

10 Without being bound by any theory or mechanism, increased levels of thrombin inhibitors, such as PN-1, in STZ-induced diabetic rats is potentially an intrinsic protection mechanism employed by the nerves to avoid PAR-1 over activation by the elevated thrombin-like activities presented in Figure 1. In addition, the increased thrombin-inhibitor levels in diabetic rats may indicate the need to regulate PAR-1 activating-proteases.

Example 4. Therapeutic effect of thrombin-inhibitors on electrophysiological parameter in vivo

15 Electrophysiological tests of the sciatic nerves were performed on day 32 PI (post-immunization/induction) in EAN model (Figs. 3A-C) and 8 weeks after STZ induction (Fig. 4A-C). Rats were anesthetized with Phenobarbital (IP, 24mg/kg). Two pairs of monopolar needle electrodes were used to stimulate the tail nerves. Stimulating cathodes were inserted to a depth of 4-5mm at the base of the tail and 4 cm distally. An anode at each location was inserted into the skin (4-5 mm depth) 1 cm proximal to the cathode. A ground electrode was placed between the distal stimulating electrode and the active recording electrode. Electromyography (EMG) recordings of responses of the tail muscles to proximal and distal stimuli, made by a pair of ring electrodes coated with electrode jelly and placed 1 cm distally to the distal stimulating electrode, were collected. The tail skin was wiped with alcohol prior to placing the electrodes. The EMG output was displayed on a fully digital recording Keypoint apparatus (Dantec, Skovlunde, Denmark). Both proximal and distal latencies were measured using time intervals from the stimulus artifact to the first deflection from baseline. To calculate the motor nerve conduction velocity (MNCV), the distance between stimulating cathodes was divided by the latency difference. Amplitudes of the compound muscle action potential (CMAP) from both proximal and distal stimulations were measured from the negative to the positive peaks. The reduction of the proximal CMAP compared with that of the distal CMAP was calculated by the equation: [(distal CMAP-proximal CMAP)/distalCMAP $\times$ 100] and was defined as the R ratio.

Temperature differences were minimized by conducting the study as soon as the anesthesia had taken effect and by warming the tail with a heating lamp.

Data was collected from EAN rats (Fig. 3) and STZ rats (Fig. 4) treated daily with the following thrombin-inhibitors: (i) N alpha-tosyl-L-lysine chloromethyl ketone (TLCK) and (ii) 5 Nα-(2-naphthyl-sulphonyl-glycyl)-DL-p-amidinophenylalanyl-piperidine (NAPAP), for 2 weeks.

Figures 3 and 4 each include 3 graphs summarizing the results from electrophysiological tests of treated rats, as follows: distal latency (3A, 4A) referring to the time, in milliseconds, between distal stimulation to recording; conduction velocity (3B, 4B) 10 referring to the distance over time, in meters/seconds; and amplitude (3C, 4C) referring to the size of the response as measured in millivolts.

EAN and STZ rats which were not treated with TLCK or NAPAP (Fig. 3B, 'EAN' bar, and Fig. 4B, 'STZ' bar) exhibited a significantly reduced conduction velocity relative to control (Figs. 3B and 4B, black bars; *= p<0.05, **= p<0.01, ***= p<0.001). Conduction velocity in 15 rats treated with TLCK was significantly high compared to the saline treated EAN and STZ control groups (*= p<0.05, **= p<0.01, ***= p<0.001; STZ+TLCK: 41.95±3.9 m/sec n=8 and STZ: 28.5±2.8 m/sec n=4, p=0.001 Fig. 3B, EAN+TLCK: 40.55±6.7 m/sec n=6 EAN: 23.6±1.2 m/sec n=5, p=0.05). NAPAP treatment group showed some improvement in conduction velocities compared to the unaffected control group (EAN+NAPAP: 36.05±3.57 m/sec, n=5 20 and EAN: 23.6±1.2 m/sec, n=5, p=0.003, Figure 3B; STZ+NAPAP: 40.1±2.7 m/sec n=5 and STZ: 28.5±2.8 m/sec n=5, p=0.01, Figure 4B). TLCK treatment increased proximal amplitude (EAN 0.76±0.33, EAN+NAPAP 0.83±0.4, EAN+TLCK 1.36±0.49), in a non-significant manner (Fig. 3B). The beneficial effect on the proximal amplitude observed in the STZ model (Fig. 4C) was also insignificant: STZ+TLCK 1.81± 0.8 (n=8), STZ+NAPAP 1.68±0.64 (n=5) 25 compared to STZ: 0.48±0.13 (n=5).

Latency, the time between induction and nerve conduction, was also measured. The results indicate that in the STZ group an increased latency was 1.93±0.139 msec (n=5) compared to control (1.29±0.057 msec, n=4). The NAPAP and TLCK treatments caused decreased latencies of 1.676±0.132 msec (n=5, p=0.11) and 1.44±0.04 msec (n=5, p=0.0019), 30 respectively. In the EAN group an increased latency was detected (1.43±0.023 msec, n=5) compared to control (0.54±0.03 msec, n=3). The NAPAP and TLCK treatments did not caused decreased latencies (1.32±0.33 msec, n=5, p=0.39, 1.28±0.18 msec, n=5, p=0.27, respectively).

The results indicate that treatment with thrombin inhibitors improves nerve conduction in an animal model for diabetes. This outcome was however accompanied by internal bleeding.

Example 5. PAR-1 expression level ex-vivo in brain homogenates of an animal model for ALS (SOD-1 mice)

The expression level of PAR-1 was measured in brain homogenates derived from SOD-1 and wild type control mice.

Figure 5 depicts a Western blots (A) and the corresponding analysis, performed with ImageJ software, from several independent experiments (B), of PAR-1 expression levels in brain homogenates of four SOD-1 mice, as compared to five healthy controls. The results demonstrate a significant decrease (2.8 fold decrease) in the expression of PAR-1 in SOD-1 mice compared to wild-type controls ($p < 0.001$). The results may indicate that interfering with the PAR-1 pathway and protecting PAR-1 from over-activation would be beneficial in treating neuropathic diseases and disorders.

Example 6. Survival experiment of ALS (SOD-1) mice treated with general thrombin inhibitors

ALS (SOD-1) mice were randomly divided into three groups, and were either untreated (diamond), treated with a relatively general thrombin inhibitor, N alpha-tosyl-L-lysine chloromethyl ketone (4.4 mg/kg TLCK; circle-), or treated with a PAR-1 antagonist (25 μ g/kg SCH79797; triangles).

The results indicate that survival without treatment did not last more than 145 days. However, treatment with either PAR-1 antagonist or with a thrombin inhibitor improved survival by at least 15 days (Figure 6). Since PAR-1 is decreased as the disease progresses, utilizing a specific PAR-1-based thrombin inhibitor in advanced stages of the disease seems more reasonable than utilizing a PAR-1 antagonist.

Example 7. Thrombin-like activity in glioma cell lines

Thrombin-like activity was measured in C6 and CNS-1 glioma cell-lines and their surrounding medium (Figures 7A and 7B, respectively), four hours after cells were treated with the highly selective thrombin inhibitor N α -(2-naphthyl-sulphonyl-glycyl)-DL-p-

amidinophenylalanyl-piperidine, NAPAP (Figs. 7A-7B, grey bars). Results are demonstrated relative to control, non-treated, cells (Figs. 7A-7B, black bars).

It is evident from Figure 7 that (a) thrombin-like activity was restricted to the cells themselves, with no apparent activity in the surrounding medium, and (b) thrombin-like activity was inhibited by NAPAP in both cell lines. Since thrombin is known to increase the proliferation of glioma cells, the glioma cell-lines endogenous generation of thrombin-like activity indicates the potential beneficial effect of thrombin specific inhibitor as proliferation regulators in gliomas such as Glioblastoma multiform (GBM).

10 **Example 8. Proliferation-inhibition of glioma cell lines by a PAR-1 antagonist**

Several peptide moieties (Table 1) according to the present invention were synthesized. Proliferation was measured, by means of XTT, in C6 and CNS-1 glioma cell-lines (Figures 8A and 8B, respectively). In C6 cells, proliferation was measured before (black bar) and after cells were treated with the PAR-1 antagonist SCH79797 at various doses ranging from 10 nM to 10 μ M (grey bars; Fig. 8A). In CNS-1 cells, proliferation was measured before (black bar) and after cells were treated with the PAR-1 antagonist SCH79797 (1 μ M), the thrombin inhibitor NAPAP, the thrombin inhibitor TLCK, or combinations thereof (grey bars; Fig. 8B).

It is evident from Figure 8A that the PAR-1 antagonist inhibited proliferation in a dose-dependent manner in C6 cells. Furthermore, according to the results presented in Figure 8B, NAPAP (1 μ M) or TLCK (1 μ M) did not inhibit proliferation of CNS-1 cells when administered alone. However, combining NAPAP or TLCK with a PAR-1 antagonist seems to improve the inhibitory effect of the PAR-1 antagonist.

Table 1. Amino-acid sequences of peptide moieties.

SEQ ID	Amino-acid sequence	Peptide Name
-	DPR	3AA
SEQ ID NO: 1	LDPR	4AA
SEQ ID NO: 2	TLDPR	5AA
SEQ ID NO: 3	ATLDPR	6AA
SEQ ID NO: 4	NATLDPR	7AA
SEQ ID NO: 5	TNATLDPR	8AA

SEQ ID NO: 6	ATNATLDPR	9AA
SEQ ID NO: 7	KATNATLDPR	10AA
SEQ ID NO: 8	SKATNATLDPR	11AA
SEQ ID NO: 9	ESKATNATLDPR	12AA
SEQ ID NO: 10	PESKATNATLDPR	Segment of the binding site on the receptor PAR-1
SEQ ID NO: 11	RPESKATNATLDPR	14AA
SEQ ID NO: 12	RRPESKATNATLDPR	15AA
SEQ ID NO: 13	ARRPESKATNATLDPR	16AA
SEQ ID NO: 14	RARRPESKATNATLDPR	17AA
SEQ ID NO: 15	TRARRPESKATNATLDPR	18AA
SEQ ID NO: 16	RTRARRPESKATNATLDPR	19AA
SEQ ID NO: 17	ARTRARRPESKATNATLDPR	C' terminus segment of PAR-1
SEQ ID NO: 18	LDPRSFLLRNPNDKYEPF	amino-terminal exodomain of PAR-1
SEQ ID NO: 19	KYEPF	hirudin-like motif

The peptide moieties were derived from the C'-terminus of PAR-1. A comparison between the amino acid (AA) sequence upstream and downstream to thrombin cleavage-site in human, mouse, rat and bovine indicates that these sequences are by and large conserved (Table 2). The position of the amino acids corresponding to the thrombin cleavage site is indicated for each sequence in the second column of Table 2 and the designed peptide length is indicated in the third column of this Table. Positions 35-47 represent part of the N-terminal of PAR-1, also termed P1-P7, designating the position upstream to the cleavage site.

Table 2. PAR-1 amino-acids sequence upstream and downstream to thrombin cleavage-site in human, mouse, rat and bovine.

		Thrombin													
		cleavage	P	P	P	P	P	P	P						
Species	site		7	6	5	4	3	2	1						
			3	3	3	3	3	4	4	4	4	4	4	4	4
		Position	5	6	7	8	9	0	1	2	3	4	5	6	7
PEPTID															
Human	41-42	E	N	A	T	L	D	P	R	S	F				
		3AA					D	P	R						
		4AA				L	D	P	R						
		5AA			T	L	D	P	R						
		6AA		A	T	L	D	P	R						
		7AA	N	A	T	L	D	P	R						
PEPTID															
Mouse	41-42	E	D	A	T	V	N	P	R	S	F				
		3AA					N	P	R						
		4AA				V	N	P	R						
		5AA			T	V	N	P	R						
		6AA		A	T	V	N	P	R						
		7AA	D	A	T	V	N	P	R						
PEPTID															
Rat	45-46	E					Y	A	T	P	N	P	R	S	F
		3AA									N	P	R		
		4AA								P	N	P	R		
		5AA							T	P	N	P	R		
		6AA						A	T	P	N	P	R		
		7AA					Y	A	T	P	N	P	R		
PEPTID															
Bovine	41-42	E	N	G	T	L	G	P	R	S	F	F	L	R	N

3AA				G	P	R	
4AA			L	G	P	R	
5AA		T	L	G	P	R	
6AA		G	T	L	G	P	R
7AA	N	G	T	L	G	P	R

Furthermore, PAR-1 antagonist (1 μ M) alone caused a significant 25% proliferation-inhibition in CNS-1 cells, wherein a combined treatment of the PAR-1 antagonist with NAPAP or TLCK significantly increased said inhibitory effect. The decreased proliferation of glioma cells in response to PAR-1 pathway modulation is a major finding, suggestive of the potential of PAR-1-based compounds as thrombin inhibitor for treating neuropathy and glioma, such as, GBM.

In another set of experiments, CNS-1 glioma cell-line was treated with increased doses of TLCK (125 nM to 14 mM), for 48 hours (Fig. 9; grey bars). Proliferation was measured by means of XTT in comparison to non-treated cells (control; black bar). High concentrations of TLCK (6.7mM, 14mM) caused cell death, and at the micro-molar range (8-33 μ M) a significant proliferation-inhibition occurred. No significant proliferation-inhibition was seen between 1 μ M to 125nM

It is therefore evident that the highly effective thrombin inhibitor TLCK decreased glioma-cell proliferation at relatively high concentrations (i.e. higher than 1 μ M), with the downside of increased risk for hemorrhage. The new PAR-1-based conjugates provided by the present invention provide the required activity at significantly lower concentrations and are devoid of harmful side effects, as demonstrated in the following Examples.

Example 9. Inhibition of cell proliferation

Initially, CNS-1 glioma cells were treated with increased concentrations of two peptide conjugates: a short conjugate of the formula tosyl-DPR-CK (comprising 3 amino acids, 3AA) or a long conjugate of the formula tosyl-NATLDPR-CK (comprising 7 amino acids, 7AA; SEQ ID NO: 4) in concentrations of 100pM, 1 nM and 10nM, for 48 hours (Fig. 10). Figure 10 provides the results of an XTT assay used for assessing cell proliferation. The results indicate that the short conjugate (3AA) caused significant inhibition of cell proliferation at 1nM and

higher inhibition at 10nM, while the long conjugate (7AA) caused a significant inhibition at 10nM, relative to untreated control (Fig. 10).

CNS-1 glioma cells were treated with increased concentrations of the peptide conjugates containing the peptide DPR or the peptides of SEQ ID NOs: 2-4 for 48 hours and for 72 hours (Figs. 11 and 12, respectively). As seen in Figure 11, a trend to reduced proliferation was observed in the samples treated with the peptide conjugates compared to controls at 48 hours. Significant inhibition, relative to untreated controls, was noted for 10 μ M peptide conjugate encompassing the peptides 6AA and 7AA ($p<0.05$). At the 72 hour experiment (Fig. 12) significantly lower proliferation was found for all concentrations of the peptide conjugate containing the 6AA peptide compared to controls ($p<0.05$). This observation was most significant at concentrations of 1 and 10 micromolar ($p=0.002$ and 0.003 , respectively). Similar inhibitory effect was observed under treatment with the peptide conjugate that includes the 3AA peptide, at all tested concentrations, compared to controls ($p<0.05$). The results indicate that the inhibition of cell proliferation as exhibited by the peptide conjugates is significantly greater than cell proliferation of the control cells, namely, cells not incubated with any of the peptide conjugates. Moreover, the inhibitory effect exerted by the peptide conjugate was prominent even at concentrations as low as the range of micromolars and nanomolars.

Example 10. Proliferation inhibition relative to PAR-1 inhibitory activity

The effect of the peptide conjugate alone, or in combination with PAR-1 antagonist, SCH79797, on cell proliferation was determined in comparison to untreated cells or cells treated with PAR-1 antagonist (Fig. 13). The results indicate that the peptide conjugate, as exemplified by a conjugate comprising the peptide set forth in SEQ ID NO:4, induces a greater inhibition on cell proliferation when applied alone or in combination with PAR-1 antagonist, compared to control (untreated cells) and even compared to PAR-1 antagonist alone.

Example 11. Anti-thrombin-activity ex-vivo

The activity of high concentrations (0.05U/ml) of thrombin (Figs. 14-14B; diamond) was measured after treatment with a wide dose-range of either the short conjugate (Figure 14A, tosyl-DPR-CK, 3AA) or the long conjugate (Figure 14B, tosyl-NATLDPR-CK, 7AA). Measurements were carried out in a thrombin inhibition non-cellular assay, which included a buffer, thrombin and a specific thrombin substrate which its cleavage indicates thrombin activity or inhibition. The conjugates concentrations applied were as follows: control (no

treatment – 0 nM; full diamond), 1mM (vertical line), 50 μ M (circle), 10 μ M (cross), 1.25 μ M (square) and 156 nM (triangle).

The data presented in Figures 14A-14B demonstrate that both peptide-conjugates have the ability to exert a complete inhibition of thrombin activity at a wide range of concentration, ranging from as high as 1 mM to as low as 156 nM.

Figure 15 presents thrombin activity in the presence of peptide conjugates containing the peptide DPR (also termed 3AA; Fig. 15: x symbols on grey line) or the peptides set forth in SEQ ID NOs: 1-4 (also termed 4AA-7AA, respectively; Fig. 15: 4AA- x symbols on dark line, 5AA – triangles, 6AA – squares, 7AA - diamonds) determined in a non-cellular system as described above. The corresponding IC₅₀ of peptide conjugates are listed in Table 3 below. These results demonstrate the efficacy of the peptide conjugates in inhibiting bovine serum thrombin.

Table 3. IC₅₀ of the peptide conjugates

IC ₅₀	Peptide encompassed in the conjugate (SEQ ID NO.)
700 pM	3AA
-	[§] 4AA (1)
700 pM	5AA (2)
700 pM	6AA (3)
100 pM	7AA (4)

[§]Results were inconsistent

Example 12. Anti-thrombin-activity in CNS-1 cells

The thrombin-like activity of CNS-1 cells was initially measured in control cells and in cells treated with (i) the short peptide conjugate (tosyl-DPR-CK, corresponding to a conjugate that includes the peptide termed 3AA) or (ii) the long conjugate (tosyl-NATLDPR-CK, corresponding to a conjugate that includes the peptide termed 7AA (SEQ ID No. 4)) at high (10 mM) and low (100 nM) concentrations (Fig. 16).

At all range of concentrations, the peptide-conjugates induced a significant inhibition of thrombin-like activity generated by CNS-1 glioma cells.

Figure 17 presents thrombin activity in the presence of peptide conjugates containing the peptide DPR (also termed 3AA; Fig. 17: asterisk) or the peptides set forth in SEQ ID NOs: 1-4 (also termed 4AA-7AA, respectively; Fig. 17: 4AA-x, 5AA-triangle, 6AA-square, 7AA-diamond) determined in rat glioma cells as described above. The corresponding IC₅₀ of peptide conjugates are listed in Table 4 below:

Table 4. IC₅₀ of the peptide conjugates in rat glioma cells

IC ₅₀	Peptide encompassed in the conjugate (SEQ ID NO.)
7 pM	3AA
-	4AA (1)
700 pM	5AA (2)
700 fM	6AA (3)
10 pM	7AA (4)

10 **Example 13. Plasma concentrations of the conjugates *in-vivo***

The concentrations of the peptide conjugates in the plasma of animals treated therewith was evaluated by a unique method that was based on the ability of the peptide conjugates to inhibit thrombin activity. Data was obtained for conjugate peptides comprising the peptide DPR and the peptides set forth in SEQ ID NO: 2; SEQ ID NO: 3; and SEQ ID NO: 4 (Figures 18A-18D, respectively). The essay initiated by obtaining blood samples from animals which received the peptide conjugates (100 microliter containing 2 micromolar, i.p.). The blood samples, after being maintained in citrate buffered sample tubes, were subjected to centrifugation for plasma separation. Samples were then filtered through a membrane with a 10 kD molecular weight cutoff which excluded all blood coagulation factors (by addition of calcium to neutralize the anticoagulation effect of the citrate buffer). Coagulation factor-free plasma samples were then applied to the thrombin activity assay.

The resulting thrombin activities in each plasma sample either diluted (x10) or *as is* were given in arbitrary units (Figs. 18-18D, diagonal shading and dotted bars, respectively). However, the actual concentration were deduced by comparing the activities to calibrated activities generated with known concentrations of the conjugate peptides. The calibration data included the following thrombin activities: activity in a sample of thrombin in the absence of plasma and conjugates (black bars, Figs. 18A-18D); and activity in four samples of thrombin and known concentrations of the peptide conjugates (10 nM, 100 nM, 1 micromolar and 10 micromolar; bars 2nd to 5th from right in Figs. 18A-18D). The comparison to calibration data indicates that an i.p. injection of 100 μ l containing 2 micromolar of each peptide conjugate resulted in a serum concentration of about 1 μ M for the peptide conjugate containing the 3AA peptide, less than 10 nM for the peptide conjugates containing the 5AA and 6AA peptides, and about 10 nM for the peptide conjugates containing the 7AA peptide. The results also suggest that the assay used herein is suitable for measuring the levels of the peptide conjugate and to identify significant differences in their distribution and stability *in vivo*.

15

Example 14. The effect of the peptide conjugates on blood coagulation

Tables 5-9 below represent the effect of the peptide conjugates comprising the peptide DPR and the peptides set forth in SEQ ID NOs: 1-4 on the following standard blood coagulation tests: Prothrombin time (PT, Table 5), activated Partial thromboplastin time (aPTT, Table 6), thrombin time (TT, Table 7), Factor Xa activity (Fxa; Table 8) and Protein C activity (Table 9) using standard hematology lab tests. For each test the most potent peptide conjugate to least potent were scored from (1) to (5). In the PT and PTT tests only very high concentrations (100 μ M) of the peptide conjugate significantly affected coagulation. Since a selection towards the conjugates least likely to affect coagulation systemically was applied, the peptide conjugate having the 3AA peptide stood out as having significantly more deleterious effects on coagulation. The most sensitive test for verifying the effect of the peptide conjugates in general was TT. Without being bound to any theory or mechanism, it is assumed that the TT test was most sensitive because it supports the mechanism of action of the peptide conjugates as direct thrombin inhibitors. Thus, the TT test indicates that the conjugates are useful inhibitors. Moreover, the results suggest that the peptide conjugate exert their therapeutic activity without interfering with coagulation. This is an outstanding benefit, as the current thrombin inhibitors cause internal bleeding.

30

Table 5. Prothrombin time test

PT	0	10nM	1 μ M	100 μ M (Potency)
3AA	11.5	11.5	12.3	FAILED(1)
4AA	11.5	11.5	11.4	12.7 (5)
5AA	11.5	12.1	11.5	14.5 (4)
6AA	11.5	11.5	11.4	16.5 (3)
7AA	11.5	11.5	11.2	17.4 (2)

Table 6. Activated Partial thromboplastin time test

aPTT	0	10nM	1 μ M	100 μ M (Potency)
3AA	30.5	30	38.1	150 (1)
4AA	30.5	30.8	30.9	42.6 (5)
5AA	30.5	30.1	30.5	63.9 (4)
6AA	30.5	30	30.6	67.6 (3)
7AA	30.5	29.9	30.7	85.2 (2)

5 **Table 7.** Thrombin time test

TT	0	10nM	1 μ M (Potency)	100 μ M
3AA	13.4	14.1	>80 (1)	>80
4AA	13.4	13.5	14.6 (5)	>80
5AA	13.4	13.8	17.8 (4)	>80
6AA	13.4	13.9	18.5 (3)	>80
7AA	13.4	13.5	24.1(2)	>80

Table 8. Factor Xa activity test

Fxa	0	1μM	100μM (Potency)
3AA	0.11	0.21	FAILED (1)
4AA	0.11		0.11 (5)
5AA	0.11		0.13 (4)
6AA	0.11		0.36 (3)
7AA	0.11		0.43(2)

Table 9. Protein C activity test

aPC	0	1μM	100μM (Potency)
3AA	109	107	FAILED (1)
4AA	109	108	66 (5)
5AA	109	109	20 (3)
6AA	109	108	11 (2)
7AA	109	110	25 (4)

5 **Example 15. Conduction velocities in the sciatic nerve of an animal model for diabetic neuropathy**

Streptozotocyn (STZ) was dissolved in citrate buffer pH 4.5 and a single dose of STZ was administered IP (140 mg/kg) to 12 weeks BALB/c mice. Hyperglycemia (over 300mg/dl blood glucose) was observed in 90% of the mice in 3 repeated measurements within a week from the STZ injection. Mice developed diabetic neuropathy developed within 4 weeks after the induction of diabetes. Mice were treated daily with sham (STZ), or with the a peptide conjugate as the active drug, exemplified by the conjugate T6AACK (i.e. a conjugate comprising the peptide set forth in SEQ ID NO:3) injected in 100 microliter volume containing the following doses: 10 nM, 100nM and 1 micromolar. A group of normal mice without diabetes served as controls.

Conduction velocities in the sciatic nerves of the mice were assessed by standard electrophysiology nerve conduction methods by a blind assessor (Fig. 19). T-test analysis of

indicated that the effect of the peptide conjugate T6AACK relative to sham treated mice was highly significant: 1 micromolar, $p=0.00046$ and 10 nM, $p=0.016$.

Thus, the conduction velocity of the sciatic nerve in diabetic mice treated with the peptide conjugate resembled that of normal, health mice.

5

Example 16. Tumor size and edema in GBM animal model

The therapeutic effect of the peptide conjugate was determined in-vivo in an animal (rat) model of GBM using a peptide conjugate that includes the 6AA peptide (SEQ ID NO: 3).

Cells (0.5×10^6 cells) from a highly malignant cell line of rat Glioblastoma multiforme (GBM) were injected by stereotactic methods into the parietal cortex of rats. Five (5) days later the brain of these rats were examined by MRI and the tumors scored on a scale of 1-3 (1-small size tumor, 2-middle size tumor, 3-large size tumor) and for ventricular localization of the tumor. A catheter was placed in the brain tumor and attached to an osmotic pump (Alzet) releasing 1 μ l/h for 7 days of one of the following three (3) treatments: saline ($n=13$), 6AA 2 μ M ($n=14$) and 6AA 20 μ M ($n=14$). Following seven (7) days of treatments an MRI was performed and the size of the tumor and edema surrounding the tumor was analyzed by standard ROI manual techniques for each rat and summarized for all three groups of treatment (1) control; (2) treatment with 2 μ M of a peptide conjugate comprising the peptide termed 6AA (SEQ ID NO: 3); and (3) treatment with 20 μ M of a peptide conjugate comprising the peptide termed 6AA (SEQ ID NO: 3).

In order to account for the unequal distribution of initial tumor size, tumor and edema analyses were performed on rats with grade 1 and 2 tumors in the initial MRI ($n=7$, 6 and 5 for the saline, low and high treatment groups, respectively). The results for the changes in tumor size (i.e. the size obtained in second (post treatment) MRI minus the size in initial (baseline, $t=0$) MRI) and similarly change in edema are presented in Figures 20 and 21, respectively. As shown by Figs. 20 and 21, high dose treatment reduced tumor size to half of the original size ($p=0.030$, t-test). A similar trend was observed for the low dose group. In addition, both doses caused reduction in the edema surrounding the tumors.

Survival was registered daily (Fig. 21). None of the 3 rats with severe initial tumors (grade 3 or ventricular) survived to perform the second MRI, compared to all 3 severe tumor rats in the high dose (6AA 20 μ M) treatment group and 1 out of 3 in the low dose group ($p=0.05$ for the high dose group compared to controls and $p=0.024$ for the high dose group compared to the other 2). As shown in Figure 21, there was a clear trend to increased survival in the high dose

30

20 μ M group and this group included 2 mice with exceptionally long survival which is borderline in significance to no survival in the other groups ($p=0.055$ by Fisher's exact test).

The foregoing description of the specific embodiments will so fully reveal the general
5 nature of the invention that others can, by applying current knowledge, readily modify and/or
adapt for various applications such specific embodiments without undue experimentation and
without departing from the generic concept, and, therefore, such adaptations and modifications
should and are intended to be comprehended within the meaning and range of equivalents of
the disclosed embodiments. It is to be understood that the phraseology or terminology
10 employed herein is for the purpose of description and not of limitation. The means, materials,
and steps for carrying out various disclosed functions may take a variety of alternative forms
without departing from the invention.

CLAIMS

1. A peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C'-terminus of PAR-1 as set forth in SEQ ID NO: 17, or an active variant thereof and a protease-disabling moiety.
5
2. The peptide conjugate of claim 1, wherein the alpha-amino protecting moiety is bound to the N'-terminus amino acid sequence of the peptide directly or via a linker.
3. The peptide conjugate of claim 1, wherein the protease-disabling moiety is bound to the C'-terminus amino acid sequence of the peptide directly or via a linker.
- 10 4. The peptide conjugate of claim 1, wherein the alpha-amino protecting moiety is tosyl or derivatives thereof.
5. The peptide conjugate of claim 1, wherein the peptide comprises the amino acid sequence Asp-Pro-Arg.
- 15 6. The peptide conjugate of claim 5, wherein the peptide comprises an amino acid sequence as set forth in any one of SEQ ID NO:1 to SEQ ID NO:17 and Asp-Pro-Arg, or an active variant thereof.
7. The peptide conjugate of claim 1, wherein the protease-disabling moiety is a substituted acetyl.
- 20 8. The peptide conjugate of claim 1, wherein the alpha-amino protecting moiety is tosyl or a derivative thereof, the peptide comprises the amino acid sequence Asp-Pro-Arg or an active variant thereof and the protease-disabling moiety is a haloacetyl.
9. A pharmaceutical composition comprising a peptide conjugate and a pharmaceutically acceptable carrier, said peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C'-terminus of PAR-1 as set forth in SEQ ID NO: 17, or an active variant thereof and a protease-disabling moiety.
25
10. The pharmaceutical composition of claim 9, further comprising trichloroacetate.
11. The pharmaceutical composition of claim 9, further comprising a PAR-1 antagonist.
- 30 12. Use of a pharmaceutical composition comprising a peptide conjugate and a pharmaceutically acceptable carrier, said peptide conjugate comprising an alpha-amino

protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C'-terminus of PAR-1 as set forth in SEQ ID NO: 17, or an active variant thereof and a protease-disabling moiety, for the treatment of a disease or disorder associated with excessive protease receptor activity.

5 13. The use of claim 12, wherein the protease receptor is PAR-1.

 14. The use of claim 12 wherein said disease or disorder is selected from the group consisting of neuroinflammation, neuroinflammatory diseases or disorders, neurodegenerative disease or disorder, neuropathy and diabetes-related neuropathy.

 15. The use of claim 12 wherein treatment comprises inhibition of the progression
10 of said disease or disorder, attenuation of the progression of said disease or disorder or prevention deterioration of said disease or disorder.

 16. A method of treating a disease or disorder associated with excessive protease
receptor activity in a patient in need of such treatment, comprising administering to said patient
a therapeutically effective amount of a pharmaceutical composition comprising a peptide
15 conjugate and a pharmaceutically acceptable carrier, said peptide conjugate comprising an
alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-
acid long derived from the C'-terminus of PAR-1 as set forth in SEQ ID NO: 17, or an active
variant thereof and a protease-disabling moiety.

 17. The method of claim 16, wherein the subject in need thereof is a subject afflicted
20 with said disease or disorder or a subject susceptible to said disease or disorder.

 18. The method of claim 16, further comprising administering a second therapeutic
agent in combination with said peptide conjugate.

 19. The method of claim 18, wherein the second therapeutic agent is a PAR-1
antagonist.

25 20. Use of a pharmaceutical composition comprising a peptide conjugate and a
pharmaceutically acceptable carrier, said peptide conjugate comprising an alpha-amino
protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long
derived from the C'-terminus of PAR-1 as set forth in SEQ ID NO: 17, or an active variant
thereof and a protease-disabling moiety, for inducing a reduction in thrombin activity.

1/26




FIGURE 1A




FIGURE 1B

2/26




FIGURE 2A




FIGURE 2B

3/26




FIGURE 2C




FIGURE 2D

4/26




FIGURE 3A




FIGURE 3B

5/26




FIGURE 3C




FIGURE 4A

6/26




FIGURE 4B




FIGURE 4C

7/26




FIGURE 5A




FIGURE 5B

8/26




FIGURE 6

9/26




FIGURE 7A




FIGURE 7B

10/26




FIGURE 8A




FIGURE 8B

11/26




FIGURE 9

12/26




FIGURE 10

13/26




FIGURE 11A




FIGURE 11B

14/26




FIGURE 11C




FIGURE 11D

15/26




FIGURE 12A




FIGURE 12B

16/26




FIGURE 12C




FIGURE 12D

17/26




FIGURE 13

18/26




FIGURE 14A




FIGURE 14B

19/26




FIGURE 15

20/26




FIGURE 16




FIGURE 17

22/26




FIGURE 18A




FIGURE 18B

23/26




FIGURE 18C




FIGURE 18D

24/26




FIGURE 19

25/26




FIGURE 20A




FIGURE 20B

26/26




FIGURE 21

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL2015/050488

A. CLASSIFICATION OF SUBJECT MATTER

IPC (2015.01) C07K 7/02, C07K 5/02, A61K 38/04, A61P 25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC (2015.01) C07K, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Databases consulted: NCBI, BLAST, THOMSON INNOVATION, Google Patents, CAPLUS, MEDLINE, REGISTRY, WPI Data, Google Scholar
Search terms used: Par-1, alpha-amino protecting moiety, tosyl, protease-disabling moiety, acetyl, haloacetyl, neurons, glia cells, neurodegenerative disease, neuropathy, sequence search, applicant

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2013070256 A2 SCRIPPS RESEARCH INST [US]; MOSNIER LAURENT O [US]; GRIFFIN JOHN H [US] 16 May 2013 (2013/05/16) the whole document, especially paragraph 0062	1-20
A	CA 2340461 A1 SHEN GARY [CA] UNIV MANITOBA [CA] 30 Sep 2001 (2001/09/30) paragraph 0032, examples 3 and 4, table 1	1-20
A	WO 2013173676 A1 KULIOPULOS ATHAN [US]; TUFTS MEDICAL CT INC [US] 21 Nov 2013 (2013/11/21) table on page 12, page 9 lines 9-20, page 18 lines 6-15	1-20
A	WO 2011039584 A2 TSOPANOGLIOU NIKOS [GR]; MARAGOUKAKIS MICHAEL [GR]; VINORES STANLEY [US]; STRANDE JENNIFER [US]; GARTAGANIS SOTIRIOS [GR]; SIABLIS DIMITRIOS [GR] 07 Apr 2011 (2011/04/07) SEQ ID NO 4	1-20

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

“A” document defining the general state of the art which is not considered to be of particular relevance

“E” earlier application or patent but published on or after the international filing date

“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

“O” document referring to an oral disclosure, use, exhibition or other means

“P” document published prior to the international filing date but later than the priority date claimed

“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

“&” document member of the same patent family

Date of the actual completion of the international search

26 Aug 2015

Date of mailing of the international search report

27 Aug 2015

Name and mailing address of the ISA:

Israel Patent Office

Technology Park, Bldg.5, Malcha, Jerusalem, 9695101, Israel

Facsimile No. 972-2-5651616

Authorized officer

RON-COHEN Yael

Telephone No. 972-2-5651737

Box No. 1 Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:

a. ☒ forming part of the international application as filed:

☒ in the form of an Annex C/ST.25 text file.

☐ on paper or in the form of an image file.

b. ☐ furnished together with the international application under PCT Rule 13ter. 1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.

c. ☐ furnished subsequent to the international filing date for the purposes of international search only:

☐ in the form of an Annex C/ST.25 text file (Rule 13ter. 1(a)).

☐ on paper or in the form of an image file (Rule 13ter. 1(b) and Administrative Instructions, Section 713).

2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL2015/050488

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02071847 A1 TRAYNELIS STEPHEN FRANCIS [US]; JUNG E CANDICE ELAINE [US]; MCKEON ROBERT J [US]; GINGRICH MELISSA BUTLER [US] 19 Sep 2002 (2002/09/19) FIG. 3, example 2	1-20

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/IL2015/050488

Patent document cited search report	Publication date	Patent family member(s)	Publication Date
WO 2013070256 A2	16 May 2013	WO 2013070256 A2	16 May 2013
		WO 2013070256 A3	25 Jul 2013
		CA 2890583 A1	16 May 2013
		EP 2776458 A2	17 Sep 2014
		EP 2776458 A4	06 May 2015
		US 2015045283 A1	12 Feb 2015
CA 2340461 A1	30 Sep 2001	CA 2340461 A1	30 Sep 2001
		EP 1138694 A1	04 Oct 2001
		US 2004229806 A1	18 Nov 2004
		US 7582602 B2	01 Sep 2009
		US 2002045589 A1	18 Apr 2002
WO 2013173676 A1	21 Nov 2013	WO 2013173676 A1	21 Nov 2013
		US 2015216990 A1	06 Aug 2015
WO 2011039584 A2	07 Apr 2011	WO 2011039584 A2	07 Apr 2011
		WO 2011039584 A3	26 May 2011
		AU 2010302383 A1	26 Apr 2012
		AU 2010302383 B2	12 Feb 2015
		CA 2776778 A1	07 Apr 2011
		EP 2483302 A2	08 Aug 2012
		US 2008242613 A1	02 Oct 2008
		US 8227412 B2	24 Jul 2012
		US 2010197580 A1	05 Aug 2010
		US 8389476 B2	05 Mar 2013
		US 2013150298 A1	13 Jun 2013
		WO 2011087491 A2	21 Jul 2011
		WO 2011087491 A9	19 Jan 2012
WO 02071847 A1	19 Sep 2002	WO 02071847 A1	19 Sep 2002

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/IL2015/050488

Patent document cited search report	Publication date	Patent family member(s)	Publication Date
		US 2004096443 A1	20 May 2004
		US 2008125498 A1	29 May 2008